•
Sep 29, 2023

Danaher Q3 2023 Earnings Report

Danaher's third quarter performance exceeded expectations, driven by strong Biotechnology results and effective DBS execution amidst a challenging environment.

Key Takeaways

Danaher Corporation reported a 10.5% year-over-year decrease in revenues to $6.9 billion. Net earnings were $1.1 billion, or $1.51 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $2.02. The company's third quarter results include the operations of Veralto Corporation, which was spun-off on September 30, 2023.

Net earnings reached $1.1 billion, with diluted earnings per share at $1.51.

Non-GAAP adjusted diluted earnings per share stood at $2.02.

Revenue totaled $6.9 billion, reflecting a 10.5% decrease year-over-year.

Operating cash flow was $1.7 billion and non-GAAP free cash flow was $1.3 billion.

Total Revenue
$6.87B
Previous year: $7.66B
-10.3%
EPS
$2.02
Previous year: $2.56
-21.1%
Core Sales Growth
-11.5%
Previous year: 10%
-215.0%
Gross Profit
$4B
Previous year: $4.58B
-12.7%
Cash and Equivalents
$12.3B
Previous year: $5.15B
+138.4%
Free Cash Flow
$1.3B
Previous year: $1.7B
-23.5%
Total Assets
$87.7B
Previous year: $81B
+8.3%

Danaher

Danaher

Forward Guidance

For the fourth quarter 2023, the Company anticipates that non-GAAP base business core revenue from continuing operations will be down mid-single digits year-over-year. For full year 2023, the Company anticipates that non-GAAP base business core revenue from continuing operations will be down slightly year-over-year.